EMA To Coordinate GMP Inspections Via Online Portal
The EMA hopes that the use of a single portal by drug companies and EU/EEA inspectorates to coordinate on good manufacturing practice inspections will drive greater efficiency.
You may also be interested in...
The new portal is expected to provide an improved method for applying for and managing EU orphan drug designations.
Saudi Arabia has explained what information on a drug’s review will be made public following a marketing authorization decision.
Revised labeling requirements for unauthorized investigational and auxiliary medicinal products under the EU Clinical Trial Regulation have been published in the Official Journal.